NCT00768820 The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
| NCT ID | NCT00768820 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The Chaim Sheba Medical Center |
| Condition | Velocardiofacial Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2001-05 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 400 participants in total. It began in 2001-05 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
Eligibility Criteria
Inclusion Criteria: * chromosomal deletion proven by FISH examination Exclusion Criteria:
Contact & Investigator
Frequently Asked Questions
Who can join the NCT00768820 clinical trial?
This trial is open to participants of all sexes, studying Velocardiofacial Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT00768820 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT00768820 currently recruiting?
Yes, NCT00768820 is actively recruiting participants. Contact the research team at gothelf@post.tau.ac.il for enrollment information.
Where is the NCT00768820 trial being conducted?
This trial is being conducted at Petah Tikva, Israel.
Who is sponsoring the NCT00768820 clinical trial?
NCT00768820 is sponsored by The Chaim Sheba Medical Center. The trial plans to enroll 400 participants.